Who is sponsoring NCT03674229?

NCT03674229 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03674229?

Interventions in NCT03674229: Informational Intervention, Questionnaire Administration, Telephone-Based Intervention.

What condition does NCT03674229 study?

NCT03674229 studies Health Status Unknown, Obesity.

Is NCT03674229 still recruiting?

NCT03674229 is currently active, enrolled. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT03674229

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patients Navigators in Facilitating Weight Management in Obese Participants

Active, enrolled NA Last updated 16 April 2026

What this trial tests

NA trial testing Informational Intervention in Health Status Unknown in 171 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 July 2015

Primary endpoint
1 October 2030

1 October 2030

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	171
Start date	2 July 2015
Primary completion	1 October 2030
Estimated completion	1 October 2030
Sites	1 location across United States

Drugs / interventions tested

Informational Intervention
Questionnaire Administration
Telephone-Based Intervention

Conditions studied

Health Status Unknown — all drugs for Health Status Unknown →
Obesity — all drugs for Obesity →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Health Status Unknown or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies the effectiveness of patient navigators in facilitating weight management in obese participants. Health coaches or patient navigators may help more participants take part in weight management programs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Coaction Between Physical Activity and Fruit and Vegetable Intake in Racially Diverse, Obese Adults.
Heredia NI, Fernandez ME, van den Berg AE, Durand CP, et al · · 2020 · cited 14× · PMID 31722544 · DOI 10.1177/0890117119884479

Verify or expand the search:

Other trials of Informational Intervention

Trials testing the same drug.

NCT06977503 — Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers · NA · recruiting
NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
NCT06927947 — Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes · NA · recruiting
NCT06568016 — A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemi · NA · recruiting
NCT06639958 — A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home · NA · suspended

Other recruiting trials for Health Status Unknown

Currently open trials in the same condition.

NCT03234556 — Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA · NA · active not recruiting
NCT03199209 — Your Health Matters! (Tu Salud ¡Si Cuenta!): Promoting Healthy Lifestyles in Latino Families · NA · active not recruiting
NCT02194387 — Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Pos · NA · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03674229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03674229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing